Sign In
Buy NVCR
$14.13
+0.520 (+3.82%)
At Close: Jun 23, 2026
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
10:39am, Monday, 22'nd Jun 2026
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
02:00pm, Saturday, 20'th Jun 2026
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure L
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
01:34pm, Saturday, 20'th Jun 2026
LOS ANGELES--(BUSINESS WIRE)---- $NVCR--NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm.
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
12:50pm, Friday, 19'th Jun 2026
Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
09:41pm, Thursday, 18'th Jun 2026
Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday
Novocure's cancer treatment fails to meet late-stage trial goal
07:08am, Thursday, 18'th Jun 2026
Novocure said on Thursday that its cancer treatment for newly diagnosed brain tumors did not meet the main goal of a late-stage study.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy f
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing
10:12am, Tuesday, 09'th Jun 2026
This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.
3 Overlooked Stocks Set to Soar in 2026
08:45am, Tuesday, 05'th May 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
International Markets and NovoCure (NVCR): A Deep Dive for Investors
10:16am, Monday, 04'th May 2026
Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet
12:35pm, Friday, 01'st May 2026
NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-y
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
02:41pm, Thursday, 30'th Apr 2026
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
09:35am, Thursday, 30'th Apr 2026
NovoCure (NVCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.31 per share a year ago.
Novocure Reports First Quarter 2026 Financial Results
07:00am, Thursday, 30'th Apr 2026
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend su
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Hold” by Analysts
02:30am, Saturday, 25'th Apr 2026
Shares of NovoCure Limited (NASDAQ: NVCR - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports.
